Literature DB >> 6149116

The interrelationship of growth hormone (GH)-releasing factor and somatostatin in generation of the ultradian rhythm of GH secretion.

G S Tannenbaum, N Ling.   

Abstract

To further delineate the relationship between GH-releasing factor (GRF) and somatostatin (SRIF) in generation of the ultradian rhythm of GH secretion, we used two GRF peptides, human pancreas (hp) GRF-44 and rat hypothalamic (rh) GRF, and studied their interaction with SRIF by passive immunization with a specific antiserum (AS) to SRIF. Freely moving, chronically cannulated male rats were given 10 micrograms of either hpGRF-44 or rhGRF, iv, during peak (1100 h) and trough (1300 h) periods of the GH rhythm. Six-hour plasma GH profiles were obtained after pretreatment with either SRIF AS or normal sheep serum (NSS) as a control. In NSS-treated rats, the plasma GH responses to both hpGRF-44 and rhGRF were significantly greater when the peptides were administered during peak than during trough periods. Immunoneutralization with SRIF AS eliminated these differences and permitted marked GH release in response to both peptides at 1300 h. In addition, SRIF AS augmented the GRF-induced GH response at 1100 h compared with that in NSS controls. The rhGRF peptide caused significantly more GH release than hpGRF under both conditions. These results demonstrate that 1) the GH-releasing abilities of the GRF peptides vary markedly according to the time of injection; 2) the weak GRF-induced GH response observed during trough periods of the GH rhythm is due to antagonization by endogenous circulating SRIF; and 3) the rat-derived GRF may be a more potent GH secretagogue than the human-derived peptide in the rat. The findings reported here together with the available evidence provide support for the hypothesis that GRF and SRIF are secreted tonically from the hypothalamus into the hypophyseal portal blood, and that superimposed upon this steady state release is an additional 3- to 4-h rhythmic surge of each peptide, providing for integration of the ultradian rhythm of GH secretion, as observed in peripheral blood.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6149116     DOI: 10.1210/endo-115-5-1952

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  50 in total

Review 1.  Regulation of renal phosphate reabsorption during development: implications from a new model of growth hormone deficiency.

Authors:  A Haramati; S E Mulroney; M D Lumpkin
Journal:  Pediatr Nephrol       Date:  1990-07       Impact factor: 3.714

Review 2.  Growth hormone-releasing hormone and growth hormone secretagogue-receptor ligands: focus on reproductive system.

Authors:  E Arvat; L Gianotti; R Giordano; F Broglio; M Maccario; F Lanfranco; G Muccioli; M Papotti; A Graziani; E Ghigo; R Deghenghi
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

3.  Interactions of growth hormone secretagogues and growth hormone-releasing hormone/somatostatin.

Authors:  G S Tannenbaum; C Y Bowers
Journal:  Endocrine       Date:  2001-02       Impact factor: 3.633

Review 4.  The role of liver-derived insulin-like growth factor-I.

Authors:  Claes Ohlsson; Subburaman Mohan; Klara Sjögren; Asa Tivesten; Jörgen Isgaard; Olle Isaksson; John-Olov Jansson; Johan Svensson
Journal:  Endocr Rev       Date:  2009-07-09       Impact factor: 19.871

5.  Immunohistochemical and cytochemical localization of the somatostatin receptor subtype sst1 in the somatostatinergic parvocellular neuronal system of the rat hypothalamus.

Authors:  L Helboe; C E Stidsen; M Moller
Journal:  J Neurosci       Date:  1998-07-01       Impact factor: 6.167

6.  IGF-1 levels may increase paradoxically with dopamine agonist treatment for prolactinomas.

Authors:  Amit Akirov; Yona Greenman; Benjamin Glaser; Irena S'chigol; Yossi Mansiterski; Yoav Eizenberg; Ilana Shraga-Slutzky; Ilan Shimon
Journal:  Pituitary       Date:  2018-08       Impact factor: 4.107

7.  Pulsatile growth hormone secretion in normal man during a continuous 24-hour infusion of human growth hormone releasing factor (1-40). Evidence for intermittent somatostatin secretion.

Authors:  M L Vance; D L Kaiser; W S Evans; R Furlanetto; W Vale; J Rivier; M O Thorner
Journal:  J Clin Invest       Date:  1985-05       Impact factor: 14.808

8.  The paradoxical response of growth hormone (GH) to thyrotropin-releasing hormone (TRH) in constitutionally tall children involves a cholinergic pathway.

Authors:  E Arteaga; P Valenzuelaa; A Cattani; M del Valle
Journal:  J Endocrinol Invest       Date:  1989-09       Impact factor: 4.256

9.  Effect of the potentiation of cholinergic activity on the variability in individual GH response to GH-releasing hormone.

Authors:  E Mazza; E Ghigo; S Goffi; M Procopio; E Imperiale; E Arvat; J Bellone; M F Boghen; E E Müller; F Camanni
Journal:  J Endocrinol Invest       Date:  1989-12       Impact factor: 4.256

10.  A question of rhythm: recent advances in growth hormone research.

Authors:  J Hamilton
Journal:  CMAJ       Date:  1995-09-01       Impact factor: 8.262

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.